Joshi James Alumkal, MD

Joshi James Alumkal, MD

Specialty: Medical Oncology
Title: Professor
5/5
See All Ratings

To request an appointment call

734-647-8902
Joshi James Alumkal, MD
Joshi James Alumkal, MD
Medical Oncology
  • About
  • Areas of Practice
  • Expertise
  • Locations
  • Insurance
  • Education & Training
  • Research Overview
  • Links
  • Patient Ratings & Comments
  • Manage Your Profile

  • About

    Dr. Alumkal is the Wicha Family Professor of Oncology. He is the Leader of the Genitourinary Medical Oncology Section in the Hematology-Oncology Division and a Professor with tenure in the Department of Internal Medicine. He co-leads the Translational and Clinical Research Program in the Rogel Cancer Center. Dr. Alumkal’s main goal is to link laboratory and clinical scientists in order to develop more effective treatments for patients with advanced cancers, including men with prostate cancer whom he treats.

    Dr. Alumkal attended the University of Texas (UT) at Austin where he graduated summa cum laude with a B.A. in Biology. He attended medical school at Baylor College of Medicine. He completed internal medicine residency training at UT Southwestern Medical Center, where he also served as Chief Resident. He completed medical oncology training at Johns Hopkins University followed by a post-doctoral fellowship focused on cancer epigenetics at Johns Hopkins University. Subsequently, Dr. Alumkal joined Oregon Health & Science University from 2007-2019. There, Dr. Alumkal was the Co-Leader of the Prostate Cancer Section and the inaugural holder of the Wayne D. Kuni and Joan E. Kuni Foundation Endowed Chair for Prostate Cancer Research.

    Dr. Alumkal is a physician-scientist who was elected to the American Society for Clinical Investigation in 2019. The Alumkal Laboratory’s main emphasis is to understand how genes get turned off and on in advanced prostate cancers and how this process enables tumors to become resistant to standard treatments. The most important goals of Dr. Alumkal’s studies are to identify therapies that effectively target advanced prostate cancers and to conduct innovative clinical trials designed to validate the effectiveness of novel therapeutic agents.

    In his free time, Dr. Alumkal enjoys spending time with his two children and his wife Kathleen Kemmer—who is also a medical oncologist and faculty member in the Hematology-Oncology Division at the University of Michigan—reading, running, and watching/playing soccer.

    Areas of Practice

    Prostate cancer

    Locations

    • Urologic Oncology Clinic | Rogel Cancer Center 1500 E Medical Center Dr
      Floor B1 Reception E
      Ann Arbor, MI 48109-5913
      Get Directions

    Insurance Accepted

    University of Michigan Health participates with most health insurance plans.

    See our insurance details

    Education & Training

    Medical School or Training

    Baylor College of Medicine, 1998

    Residency

    University of Texas Southwestern Medical Center, Internal Medicine, 2001

    Fellowships

    Johns Hopkins School of Medicine, Oncology, 2006

    Board Certifications

    Medical Oncology

    Professional Organizations

    American Association for Cancer Research
    American Society For Clinical Investigation
    American Society of Clinical Oncology

    Research Overview

    Dr. Alumkal is focused on developing a clearer understanding of what drives advanced prostate cancer so he and his team may develop more effective treatments for men with this disease.

    Links

    Hematology & Oncology - Division of Hematology and Oncology

    Rogel Cancer Center

    Patient Ratings & Comments

    Visit our Physician Ratings & Comments page to learn more about how patient ratings are collected, calculated, and updated to help you make an informed decision when choosing the right physician for your care.

    Patient Ratings

    96 Patient Ratings

    Patient Comments

    January 15, 2026 - "Excellent is a better rating than "very good" for Dr. Alumkal."

    November 28, 2025 - "Dr. Alumkal is always professional and empathetic. Willing to listen and I never feel rushed. He takes time to answer any questions I have."

    November 13, 2025 - "Dr. Alumkal was very professional and explained everything very well."

    September 25, 2025 - "We are very glad Dr Alumkal chose to stay with Michigan Medicine. We trust his knowledge and experience and his takes the time to explain everything to us and answer all questions. He has excellent communication with his patients through the portal and seems to always have an eye on the portal. [...]"

    September 4, 2025 - "Dr Alumkal is the best kind of doctor, he is kind , thourough, knowledgeable and caring. There isn't a better doctor, so what else can be said. If he is your doctor you are very lucky and you are in good hands."

    July 31, 2025 - "Dr. Alumkal and [...] saved my life once and are at it again. [...]"

    June 19, 2025 - "Dr. Alumkal prepared very well the Patient records and remembered the important pervious items. For example, patient's previous [...] number.He guided the patient precisely what to take in the near future and after that for the next steps. He talked with easily we could understand the situations of patient.I am happy to have him for my Doctor and I strongly recommend to other people."

    May 29, 2025 - "I could not be in better care for my condition. I am very happy to have Dr Alumkal as my doctor."

    Featured News & Stories

    yellow pills spilling out of bottle
    Health Lab

    Study sheds light on why some prostate tumors are resistant to treatment

    A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment. 
    cells purple some lighter cells in white
    Health Lab

    Researchers find early driver of prostate cancer aggressiveness

    University of Michigan Health Rogel Cancer Center scientists identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an existing class of drugs, suggesting a potential treatment strategy for patients with aggressive subtypes of prostate cancer.